Exploring the mechanism of action of Jinqiancao granules against liver cirrhosis based on the liver-gut axis
This study demonstrates that JQC mitigates liver cirrhosis in mice by modulating the gut-liver axis, enhancing the intestinal barrier, and inhibiting the PI3K-AKT signaling pathway. These results propose JQC as a promising therapeutic candidate, warranting further clinical translation.
Authors
- Yongan Ye (ORCID: https://orcid.org/0000-0002-3675-9233)
- Xiangyun Zou (ORCID: https://orcid.org/0000-0002-5565-2458)
- Yaxi Zhang (ORCID: https://orcid.org/0000-0003-1394-525X)
- Xiaobin Zao (ORCID: https://orcid.org/0000-0002-7533-1301)
- Wenying Qi (ORCID: https://orcid.org/0009-0005-7210-2561)
- Xiaomei Zhang (ORCID: https://orcid.org/0000-0003-0964-8922)
- Xiaoke Li (ORCID: https://orcid.org/0000-0002-1775-3063)
- Shihao Zheng
- Qiuyue Wang (ORCID: https://orcid.org/0000-0002-3621-8736)
- Size Li (ORCID: https://orcid.org/0009-0008-3809-0183)
- Fan-E Cheng
Institutions
- Beijing University of Chinese Medicine (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fphar.2025.1686535
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China